Literature DB >> 17001771

Haemostasis.

J Arnout1, M F Hoylaerts, H R Lijnen.   

Abstract

When the continuity of the vascular endothelium is disrupted, platelets and fibrin seal off the defect. Haemostatic processes are classified as primary (mainly involving platelets) and secondary (mainly related to fibrin formation or blood coagulation). When the blood clot is no longer required for haemostasis, the fibrinolytic system will dissolve it. The pivotal ligand for initial platelet recruitment to injured vessel wall components is von Willebrand factor (vWF), a multimeric protein present in the subendothelium and in plasma, where it is conformationally activated by shear forces. Adhering activated platelets recruit additional platelets, which are in turn activated and form a platelet aggregate. Coagulation is initiated by a reaction, activating factors IX and X. Once critical amounts of factor Xa are generated, thrombin generation is initiated and soluble fibrinogen is converted into insoluble fibrin. Excessive thrombin generation is prevented via inhibition by antithrombin and also via downregulation of its further generation by activation of the protein C pathway. Activation of the fibrinolytic system results from conversion of the proenzyme plasminogen into the active serine proteinase plasmin by tissue-type or urokinase-type plasminogen activators. Plasmin digests the fibrin component of a blood clot. Inhibition of the fibrinolytic system occurs at the level of the plasminogen activator (by plasminogen activator inhibitors) or at the level of plasmin (by alpha2-antiplasmin). Together, these physiological processes act to maintain normal functioning blood vessels and a non-thrombotic state.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001771     DOI: 10.1007/3-540-36028-x_1

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  22 in total

Review 1.  [Dermatologic aspects of anticoagulation].

Authors:  V Meyer; S W Schneider; T Görge
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

Review 2.  Skin wound healing and scarring: fetal wounds and regenerative restitution.

Authors:  Cecelia C Yates; Patricia Hebda; Alan Wells
Journal:  Birth Defects Res C Embryo Today       Date:  2012-12

3.  Extensive deendothelialization and thrombogenicity in routinely prepared vein grafts for coronary bypass operations: facts and remedy.

Authors:  Dominik R Weiss; Gerd Juchem; Bernhard M Kemkes; Brigitte Gansera; Stephan Nees
Journal:  Int J Clin Exp Med       Date:  2009-05-28

Review 4.  Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells.

Authors:  Wesley M Jackson; Leon J Nesti; Rocky S Tuan
Journal:  Stem Cells Transl Med       Date:  2011-12-07       Impact factor: 6.940

5.  Intersectin-1s: an important regulator of cellular and molecular pathways in lung injury.

Authors:  Dan N Predescu; Cristina Bardita; Rajive Tandon; Sanda A Predescu
Journal:  Pulm Circ       Date:  2013-12-05       Impact factor: 3.017

6.  Plasmin is essential in preventing periodontitis in mice.

Authors:  Rima Sulniute; Tomas Lindh; Malgorzata Wilczynska; Jinan Li; Tor Ny
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

7.  Determinants of the thrombogenic potential of multiwalled carbon nanotubes.

Authors:  Andrew R Burke; Ravi N Singh; David L Carroll; John D Owen; Nancy D Kock; Ralph D'Agostino; Frank M Torti; Suzy V Torti
Journal:  Biomaterials       Date:  2011-06-12       Impact factor: 12.479

Review 8.  MicroRNAs in endothelial cell homeostasis and vascular disease.

Authors:  Carlos Fernández-Hernando; Yajaira Suárez
Journal:  Curr Opin Hematol       Date:  2018-05       Impact factor: 3.284

Review 9.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

10.  Hemostasis and inflammation: two of a kind?

Authors:  Peter Verhamme; Marc F Hoylaerts
Journal:  Thromb J       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.